



Clinical trial results:

Clinical Trial to Explore Treatment Effects of Ginkgo biloba Extract EGb 761® in Patients with Chronic Tinnitus and Effect Modification by Etiology, Biological Factors and Concomitant Pathologies.

Summary

EudraCT number	2016-000315-32
Trial protocol	PL
Global end of trial date	19 December 2017

Results information

Result version number	v1 (current)
This version publication date	14 July 2019
First version publication date	14 July 2019
Summary attachment (see zip file)	523079.01113_Summary of result_V1.0 (523079.01.113_SummaryOfResults_EUDRA_CT_Version1.0 20181022 mit Schwärzungen.pdf)

Trial information

Trial identification

Sponsor protocol code	523079.01.113
-----------------------	---------------

Additional study identifiers

ISRCTN number	ISRCTN83863387
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Dr. Willmar Schwabe GmbH & Co. KG
Sponsor organisation address	Willmar-Schwabe-Str. 4, Karlsruhe, Germany, 76227
Public contact	Head Clinical Research Department, Dr. Willmar Schwabe GmbH & Co. KG, 0049 7214005573,
Scientific contact	Head Clinical Research Department, Dr. Willmar Schwabe GmbH & Co. KG, 0049 7214005573,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	25 January 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	19 December 2017
Global end of trial reached?	Yes
Global end of trial date	19 December 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

- To explore whether causes, risk factors, chronicity, characteristics of tinnitus and accompanying features influence the treatment effect of EGb 761® in terms of improvement and response rates
- To identify groups of patients that benefit most from EGb 761®

Protection of trial subjects:

Possibility to withdraw informed consent. Monitoring of adverse Events and laboratory Parameters.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 October 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 187
Worldwide total number of subjects	187
EEA total number of subjects	187

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	154
From 65 to 84 years	33
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Subjects were recruited in twelve investigational sites in Poland.

Pre-assignment

Screening details:

Eleven patients did not receive the investigational product since they were classified as screening failures.

Pre-assignment period milestones

Number of subjects started	187
Number of subjects completed	176

Pre-assignment subject non-completion reasons

Reason: Number of subjects	Screening Failures: 11
----------------------------	------------------------

Period 1

Period 1 title	Treatment period (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	No
Arm title	Baseline

Arm description:

Baseline before starting treatment with EGb 761®

Arm type	Baseline
No investigational medicinal product assigned in this arm	

Arm title	EGb 761®
------------------	----------

Arm description:

Investigational medical product containing EGb 761®, two film-coated tablets of 120 mg Ginkgo biloba extract

Arm type	Experimental
Investigational medicinal product name	EGb 761®
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

1 film-coated tablet 2 times per day for 24 consecutive weeks

Number of subjects in period 1	Baseline	EGB 761®
Started	176	176
Completed	176	160
Not completed	0	16
Consent withdrawn by subject	-	2
Adverse event, non-fatal	-	4
Laboratory results at baseline	-	1
Lost to follow-up	-	5
Lack of efficacy	-	4

Baseline characteristics

Reporting groups^[1]

Reporting group title	Treatment period (overall period)
-----------------------	-----------------------------------

Reporting group description:

In total, 176 subjects received the investigational treatment.

Notes:

[1] - The number of subjects reported to be in the baseline period is not equal to the worldwide number of subjects enrolled in the trial. It is expected that these numbers will be the same.

Justification: In total, 11 of the 187 subjects screened for inclusion into the study were not included into the baseline period.

Reporting group values	Treatment period (overall period)	Total	
Number of subjects	176	176	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	148	148	
From 65-84 years	28	28	
85 years and over	0	0	
Age continuous			
Units: years			
arithmetic mean	51.3		
standard deviation	± 13.0	-	
Gender categorical			
Units: Subjects			
Female	65	65	
Male	111	111	

Subject analysis sets

Subject analysis set title	Full Analysis Set
----------------------------	-------------------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

The full analysis set (FAS) includes all patients who took EGb 761® treatment and have at least one value of one of the most important variables to describe treatment effects assessed after baseline.

Subject analysis set title	Safety Evaluation Set
----------------------------	-----------------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

The safety evaluable set (SES) comprises all patients having taken at least one tablet of EGb 761® .

Reporting group values	Full Analysis Set	Safety Evaluation Set	
Number of subjects	170	176	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	142	148	
From 65-84 years	28	28	
85 years and over	0	0	
Age continuous Units: years			
arithmetic mean	51.6	51.3	
standard deviation	± 13.0	± 13.0	
Gender categorical Units: Subjects			
Female	62	65	
Male	108	111	

End points

End points reporting groups

Reporting group title	Baseline
-----------------------	----------

Reporting group description:

Baseline before starting treatment with EGb 761®

Reporting group title	EGb 761®
-----------------------	----------

Reporting group description:

Investigational medical product containing EGb 761®, two film-coated tablets of 120 mg Ginkgo biloba extract

Subject analysis set title	Full Analysis Set
----------------------------	-------------------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

The full analysis set (FAS) includes all patients who took EGb 761® treatment and have at least one value of one of the most important variables to describe treatment effects assessed after baseline.

Subject analysis set title	Safety Evaluation Set
----------------------------	-----------------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

The safety evaluable set (SES) comprises all patients having taken at least one tablet of EGb 761® .

Primary: Primary end point

End point title	Primary end point ^[1]
-----------------	----------------------------------

End point description:

This document in its section "End points" specifies commercially confidential information of Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe referred to in Article 81 Section (4) b) Regulation (EU) 536/2014 that is a trade secret and released by the holder for purposes of Regulation (EU) 536/2014 only under the condition of confidence. Trade secrets may not - even in part - be published or released to third parties other than to competent authorities without express permission of the trade secret holder.

End point type	Primary
----------------	---------

End point timeframe:

Week 0 - week 24

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The reported results are chosen freely. See document for a complete description of the statistical methods and results.

Statistical analyses were conducted for the end point. Refer to the attached summary of results for details.

End point values	Baseline	EGb 761®		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	170	170		
Units: points				
median (inter-quartile range (Q1-Q3))	9999.99 (9999.99 to 9999.99)	9999.99 (9999.99 to 9999.99)		

Statistical analyses

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

27 weeks.

Adverse event reporting additional description:

Non-serious adverse events occurred in 37 patients. However, no incidence of preferred terms of adverse events was higher than the threshold of 5%.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

Reporting groups

Reporting group title	EGb 761®
-----------------------	----------

Reporting group description:

Study Medication.

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: No adverse events (AE) with an incidence higher than the threshold of 5% occurred during the trial.

Serious adverse events	EGb 761®		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 176 (0.57%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Renal and urinary disorders			
Calculus urinary			
subjects affected / exposed	1 / 176 (0.57%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	EGb 761®		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 176 (0.00%)		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported